Biosergen will conduct a new phase 1b study in patients with invasive fungal infections with its drug candidate BSG005. This will be done together with the Indian pharmaceutical company Alkem. The benefits of doing clinical studies with Alkem are that Biosergen is guaranteed that future studies will be done and that the development costs for Biosergen will be significantly lower. This is a step done to get BSG005 faster to the market. However, Biosergen must finance the phase 1b study and needs to raise capital for that. Future studies are funded by Alkem.
LÄS MER
